Cancer cells and TAMs contribute to the degradation of ECM via secretion of cytokines and protease expression alterations.99 The quantitative proteomics analysis of ECM protein composition in primary lung tumors and metastases revealed specific signatures of tumor ECM associated with metastatic process, such as fibronectin and tenascin-C are significantly accumulated.100 Moreover, TNC, S100A10 and S100A11 showed prominent potential in the prediction of patient survival, which may serve as diagnostic biomarkers and therapeutic targets in the future. The gene discussed is TNC; the disease is cancer.